The therapy of castration-resistant prostate cancer (CRPC) has made significant advances. The abiraterone, enzalutamide,
docetaxel, cabazitaxel and radium 223 provided a survival benefit. The significant number of patients showed
a significant benefit from sequential treatment.The multitude of treatment options for patients with advanced prostate
cancer clearly asks for close collaboration among urologists, medical oncologists and radiation therapists.